In the last trading session, 2.64 million shares of the ATAI Life Sciences N.V (NASDAQ:ATAI) were traded, and its beta was 1.22. Most recently the company’s share price was $2.18, and it changed around $0.06 or 2.83% from the last close, which brings the market valuation of the company to $365.81M. ATAI currently trades at a discount to its 52-week high of $2.85, offering almost -30.73% off that amount. The share price’s 52-week low was $1.03, which indicates that the current value has risen by an impressive 52.75% since then. We note from ATAI Life Sciences N.V’s average daily trading volume that its 10-day average is 4.21 million shares, with the 3-month average coming to 2.27 million.
ATAI Life Sciences N.V stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ATAI as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. ATAI Life Sciences N.V is expected to report earnings per share of -0.15 for the current quarter.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Instantly ATAI has showed a green trend with a performance of 2.83% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.48 on recent trading dayincreased the stock’s daily price by 12.1%. The company’s shares are currently up 63.91% year-to-date, but still up 40.65% over the last five days. On the other hand, ATAI Life Sciences N.V (NASDAQ:ATAI) is 24.57% up in the 30-day period. We can see from the shorts that 11.55 million shares have been sold at a short interest cover period of 6.15 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 63.67% from its current value. Analyst projections state that ATAI is forecast to be at a low of $6 and a high of $6.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
The year-over-year growth rate is expected to be 159.03%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 250k in revenue for the current quarter. Analysts predict that the company’s current quarter sales will jump, forecast at 1,288.89%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 44.19%.
ATAI Dividends
ATAI Life Sciences N.V’s next quarterly earnings report is expected to be released in March.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 10.02% of ATAI Life Sciences N.V shares, and 26.08% of them are in the hands of institutional investors. The stock currently has a share float of 28.99%. ATAI Life Sciences N.V stock is held by 101.0 institutions, with WALLEYE CAPITAL LLC being the largest institutional investor. By 2024-06-30, it held 1.7388% of the shares, which is about 2.76 million shares worth $3.67 million.
MORGAN STANLEY, with 1.7111% or 2.72 million shares worth $3.62 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
